{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-071386","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.331619+00:00","generated_at":"2026-05-31T08:16:49.497682+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed Pharma issued 3 US patents for EB treatment, biosynthesis, ocular delivery","bullets":["Patent for INM-755 cannabinoid topical for epidermolysis bullosa granted in US, Australia, Japan, Israel.","Biosynthesis patent for manufacturing proprietary analogs granted in US, issued Sept 3, 2024.","Ocular drug delivery formulation patent granted/allowed in US, Europe, Australia, Japan, India.","Total IP portfolio now 13 patent families covering NCEs, formulations, manufacturing, methods of use.","Company continues pursuing patent protection for INM-901 (Alzheimer's) and INM-089 (dry AMD)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-071386","json":"https://secwatch.observer/filing/0001213900-24-071386.json","markdown":"https://secwatch.observer/filing/0001213900-24-071386.md","text":"https://secwatch.observer/filing/0001213900-24-071386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/0001213900-24-071386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/ea0212056-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:16:49.497682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}